Electromed

Electromed, Inc. engages in the development, manufacture, marketing, and sale of medical equipment. The firm's products include SmartVest SQL System and SmartVest Connect. It focuses on building market awareness, and acceptance of its products and services with physicians, clinicians, patients, and third-party payers. The company was founded by Robert D. Hansen and Craig N. Hansen in 1992 and is headquartered in New Prague, MN.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Electromed reports record Q1 revenues, faces CMS waiver expiration

Electromed delivered robust financial performance, driven by strong revenue growth and operational efficiency. The company faces challenges related to potential CMS waiver expiration and CEO succession, but strategic initiatives and market opportunities position it for continued growth. Overall, Electromed's focus on innovation and market expansion bodes well for future success.

Electromed reports record Q2 revenue, focuses on strategic growth

Electromed's Q2 2023 earnings call showcased strong financial performance, particularly in the home care segment. Despite challenges from the expiration of the CMS waiver, the company's strategic growth initiatives and clinical evidence present promising opportunities for future success.

Electromed Inc. reports robust Q3 earnings and targets market expansion

Electromed Inc. delivered strong financial performance in Q3 2023, driven by revenue growth and improved operational efficiency. The company's strategic initiatives and focus on quality assurance position it for continued success. However, managing expenses and balancing revenue across segments will be crucial for sustained growth.

Electromed (ELMD) reports record revenue and eyes growth opportunities

Electromed's Q4 2023 earnings call showcased impressive financial performance, with record revenue and operating income. The company's strategic focus on growth investments, operational excellence, and market development is driving strong results. While facing challenges in optimizing capital deployment, Electromed is well-positioned to leverage opportunities in expanding its market presence and driving further growth.

Electromed (ELMD) achieves record revenue in Q3 2024 earnings call

Electromed (ELMD) delivered robust financial performance in Q3 2024, driven by revenue growth and operational excellence. Despite challenges like a cyberattack and increased expenses, the company remains well-positioned with a strong cash position and growth strategies in place.

Electromed (ELMD) achieves record revenue and market expansion in Q4 2024

Electromed's Q4 2024 performance reflects strong revenue growth, operational excellence, and strategic market initiatives.
While facing challenges in maintaining growth momentum, the company's focus on innovation and market expansion positions it for future success.
With a solid financial position, diverse product portfolio, and growth strategies in place, Electromed is poised for continued growth and market leadership.

Electromed (ELMD) reports robust Q1 earnings and strategic growth plans

Electromed's Q1 2025 performance reflects strong revenue growth, improved profitability, and strategic investments in key areas.
The company's financial stability, operational efficiency, and focus on market expansion position them for sustained success in the medical device industry.
While challenges in maintaining growth persist, Electromed's proactive approach to innovation and market awareness presents opportunities for future expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Electromed, Inc. Appoints Brad Nagel as Chief Financial Officer

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. to Participate in the Issuer Direct 2022 Windy City Roundup

Electromed, Inc. to Participate in the Issuer Direct 2022 Windy City Roundup

Electromed is a profitable medical device company, with a strong and growing market share, operating within an oligopoly. Valuation is currently very low, driven in part by depressed earnings, which we believe are about to reverse.

Electromed, Inc.: 2 Potential Paths To A Very Attractive Return

Electromed, Inc. (NYSE:ELMD ) Q4 2022 Earnings Conference Call August 23, 2022 5:00 PM ET Company Participants Mike Cavanaugh - IR Kathleen Skarvan - CEO and President Michelle Wirtz - Interim CFO Conference Call Participants Kyle Bauser - Lake Street Capital Markets Operator Greetings. And welcome to the Electromed Fiscal Fourth Quarter Earnings Call.

Electromed, Inc. (ELMD) CEO Kathleen Skarvan on Q4 2022 Results - Earnings Call Transcript

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. Announces Fiscal 2022 Fourth Quarter and Full Year Financial Results

Electromed, Inc. Announces Fiscal 2022 Fourth Quarter and Full Year Financial Results

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. Schedules its Fourth Quarter and Fiscal 2022 Financial Results Conference Call for August 23, 2022 at 5:00 p.m. ET

Electromed, Inc. Schedules its Fourth Quarter and Fiscal 2022 Financial Results Conference Call for August 23, 2022 at 5:00 p.m. ET

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that it has elected a new independent director, Andrew Summers, to its Board of Directors, effective July 25, 2022. In connection with the election, Electromed has entered into a new cooperation agreement with Summers Value Partners LLC (“Summers Value Partners”), an investment firm that beneficially owns approximately 6.1% of Electrome

Electromed, Inc. Announces Election of Andrew Summers as Additional Independent Director

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. to Participate in the Canaccord Genuity 42nd Annual Growth Conference

Electromed, Inc. to Participate in the Canaccord Genuity 42nd Annual Growth Conference

AFC Gamma

Allied Motion Technologies

Diversified Healthcare Trust

CarParts.com, Inc.

Sally Beauty Hlds

Wheels Up Experience

These small-cap stocks just might fly underneath the drama yet still pack enormous potential to rise up over the long haul. The post 7 Lesser-Known Small-Cap Stocks to Keep on Your Watchlist appeared first on InvestorPlace.

7 Lesser-Known Small-Cap Stocks to Keep on Your Watchlist

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (NYSE American: ELMD) today announced the results of a third-party, clinical study presented as a clinical abstract poster at the American Thoracic Society International Conference in San Francisco, CA. The study's key findings reveal that patients who used high frequency chest wall oscillation (“HFCWO”) therapy experienced an improvement in health outcomes, as well as a reduction in healthcare resource utilization (“HCRU”), including a reduc

Electromed, Inc. Announces Clinical Abstract Poster at ATS Conference: Bronchiectasis Patients Showed Improved Outcomes and Reduction in Healthcare Resource Utilization When Using HFCWO Therapy

Electromed, Inc. (NYSE:ELMD ) Q3 2022 Earnings Conference Call May 10, 2022 5:00 PM ET Company Participants Mike Cavanaugh - Investor Relations Kathleen Skarvan - President and Chief Executive Officer Mike MacCourt - Chief Financial Officer Operator Greetings. Welcome to the Electromed Fiscal Third Quarter Earnings Call.

Electromed, Inc. (ELMD) CEO Kathleen Skarvan on Q3 2022 Results - Earnings Call Transcript

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. Announces Third Quarter Financial Results

Electromed, Inc. Announces Third Quarter Financial Results

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. to Participate in the Sidoti & Co. May Micro Cap Virtual Investor Conference

Electromed, Inc. to Participate in the Sidoti & Co. May Micro Cap Virtual Investor Conference

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. Schedules its Third Quarter Fiscal 2022 Financial Results Conference Call for May 10, 2022 at 5:00 p.m. ET

Electromed, Inc. Schedules its Third Quarter Fiscal 2022 Financial Results Conference Call for May 10, 2022 at 5:00 p.m. ET

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc., Appoints Christopher Holland Chief Commercial Officer

Electromed, Inc., Appoints Christopher Holland Chief Commercial Officer

Electromed, Inc. (ELMD) CEO Kathleen Skarvan on Q2 2022 Results - Earnings Call Transcript

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. Announces Second Quarter Financial Results

Electromed, Inc. Announces Second Quarter Financial Results

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2022 second quarter ended December 31, 2021, on Tuesday, February 8, 2022 after the close of the stock market, and host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by

Electromed, Inc. Schedules its Second Quarter Fiscal 2022 Financial Results Conference Call for February 8, 2022 at 5:00 p.m. ET

Electromed, Inc. (ELMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Electromed, Inc. (ELMD) Upgraded to Buy: Here's What You Should Know

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that Kathleen Skarvan, President and Chief Executive Officer, and Mike MacCourt, Chief Financial Officer, are scheduled to participate in the Sidoti December Virtual Micro Cap Investor Conference on December 8-9, 2021. Management will be available for one-on-ones throughout both days. Below are the details for Electrome

Electromed, Inc. to Participate in the Sidoti December Virtual Micro Cap Investor Conference

Electromed, Inc. (ELMD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Bears are Losing Control Over Electromed, Inc. (ELMD), Here's Why It's a 'Buy' Now

Electromed, Inc. (ELMD) delivered earnings and revenue surprises of -16.67% and 11.12%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Electromed, Inc. (ELMD) Lags Q1 Earnings Estimates

Electromed, Inc. (ELMD) CEO Kathleen Skarvan on Q1 2022 Results - Earnings Call Transcript

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended September 30, 2021 (“Q1 FY 2022”). Q1 FY 2022 Highlights Net revenue increased 25.0% to $10.0 million, from $8.0 million for the three months ended September 30, 2020 (“Q1 FY 2021”), driven by 24.4% home care revenue growth and 61.5% institutional revenue growth. Gross profit

Electromed, Inc. Announces Fiscal 2022 First Quarter Financial Results

Electromed, Inc. (ELMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Electromed Stock (ELMD)